Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$46.97 USD
-0.05 (-0.11%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $46.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.97 USD
-0.05 (-0.11%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $46.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Zacks News
FDA Lifts Clinical Hold on Bellicum's (BLCM) T Cell Therapy
by Zacks Equity Research
Bellicum (BLCM) agrees to make amendments to the protocols relating to clinical studies evaluating its T Cell Therapy, BPX-501.
Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up
by Zacks Equity Research
Epizyme (EPZM) publishes tazemetostat phase I clinical data in The Lancet Oncology. The study demonstrated favorable safety findings and anti-tumor activity.
Spectrum Pharma Stock Up on Positive Lung Cancer Study Data
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.
The Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and Amgen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verona, Squibb, Protagonist and Amgen
Protagonist Therapeutics Stalls Ulcerative Colitis Study
by Zacks Equity Research
Protagonist Therapeutics' (PTGX) shares plunge more than 50%, following discontinuation of a mid-stage study on its key ulcerative colitis candidate, PTG-100.
Why Global Blood Therapeutics (GBT) Could Be Positioned for a Slump
by Zacks Equity Research
It seems to be a wise decision for investors to drop Global Blood Therapeutics (GBT) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Shares of BioDelivery Sciences (BDSI) rose over 5% yesterday.
Geron (GERN) in Focus: Stock Moves 10.8% Higher
by Zacks Equity Research
Geron (GERN) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
G1 Therapeutics (GTHX) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Shares of G1 Therapeutics (GTHX) rose nearly 9% yesterday.
BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
BioTime (BTX) was a big mover last session, as the company saw its shares rise 6% on the day amid huge volumes.
Penumbra (PEN) Forms JV on Virtual Reality in Health Space
by Zacks Equity Research
Penumbra's (PEN) joint venture with Sixense Enterprises indicates formation of a leading digital health platform in the field of virtual reality technology.
New Products Aid Boston Scientific, LOTUS Relaunch Lag Ails
by Zacks Equity Research
Boston Scientific (BSX) grows on product launches and international expansion. LOTUS relaunch delay hurts sales.
Thermo Fisher Buys Phenom-World, Aids Analytical Instruments
by Zacks Equity Research
On completion of Phenom-World purchase, Thermo Fisher (TMO) plans to integrate the business into its Analytical Instruments segment.
PetMed Rides on Solid Reorders & New Orders Amid Competition
by Zacks Equity Research
PetMed (PETS) strives to implement several strategies to revitalize the top line, focusing on advertising efficiency to boost new order sales and shifting sales to higher margin items.
Dicerna Pharmaceuticals (DRNA) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Pieris Pharmaceuticals (PIRS) Soars: Stock Adds 15.2% in Session
by Zacks Equity Research
Pieris Pharmaceuticals (PIRS) saw a big move last session, as its shares jumped more than 15% on the day, amid huge volumes.
PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%
by Zacks Equity Research
PDL BioPharma, Inc, (PDLI) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.
PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%
by Zacks Equity Research
PDL BioPharma, Inc. (PDLI) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals
4 Top-Ranked Biotech Stocks Under $20 With Room for Growth
by Zacks Equity Research
We take a look at the biotech stocks with a potential for growth keeping in mind that the industry has witnessed a rebound in 2017 from last year's challenges.